Skip to main content

Relevant Updates – December 2022

I’m guessing that news about possible Alzheimer’s disease treatments is still relevant to most of us, so I’ll start with that. The results of the lecanemab trial are published. The reaction is mixed. In the October “Odd & Ends” piece, I discussed in considerable detail the clinical trial of lecanemab in advance of publication of […]
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.